{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:56Z","timestamp":1787962316661,"version":"build-2784847793"},"reference-count":54,"publisher":"Baishideng Publishing Group Inc.","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i25.7795","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T04:54:55Z","timestamp":1436158495000},"page":"7795","source":"Crossref","is-referenced-by-count":33,"title":["Clinical predictors of thiopurine-related adverse events in Crohn's disease"],"prefix":"10.3748","volume":"21","author":[{"given":"Gordon W","family":"Moran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60751-X"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Frolkis A, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013;27:e18-e24.","DOI":"10.1155\/2013\/102859"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.041"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545.pub3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000067.pub2"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.04.048"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.009"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.392"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.002"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.58"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.04.023"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i39.4372"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04489.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-142.","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2011.03.023"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003;69-72.","DOI":"10.1080\/00855920310002726"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.03.016"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21221"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-489.","DOI":"10.1136\/gut.50.4.485"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02977.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.926"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.11.007"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Schwab M, Sch&auml;ffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429-436.","DOI":"10.1097\/00008571-200208000-00003"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03788.x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993;53:747-749.","DOI":"10.3109\/00365519309092580"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.09.003"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9119-z"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.3.303"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2008.187"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Th&eacute;or\u00eat Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713.","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.03.022"},{"key":"ref35","unstructured":"Booth RA, Ansari MT, Tricco AC, Loit E, Weeks L, Doucette S, Skidmore B, Hoch JS, Tsouros S, Sears M. Assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs. Evid Rep Technol Assess (Full Rep) 2010;1-282."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283545ae3"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000206544.05661.9f"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.08.026"},{"key":"ref39","unstructured":"B&eacute;nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Mumoli N, Cei M, Cosimi A. Drug-related hepatotoxicity. N Engl J Med 2006;354:2191-2193; author reply 2191-2193.","DOI":"10.1056\/NEJMc060733"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10575.x"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5A-36A.","DOI":"10.1155\/2005\/269076"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01848.x"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00843.x"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soul&eacute; JC, Modigliani R, Touze Y, Catala P. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn&rsquo;s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-1030.","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01187.x"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02520.x"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.218"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.525505"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04287.x"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03746.x"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61302-7"},{"key":"ref53","unstructured":"Mart&iacute;nez F, Nos P, Pastor M, Garrigues V, Ponce J. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig 2001;93:769-778."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, Gisholt K, Wist E, Aarbakke J. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.","DOI":"10.1038\/clpt.1992.4"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i25\/7795.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T20:56:01Z","timestamp":1566939361000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i25\/7795.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":54,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i25.7795","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}